New PET scan could sharpen prostate cancer monitoring

NCT ID NCT04158245

Completed Diagnosis Sponsor: Tulane University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This pilot study tested whether a special PET scan (18F-fluciclovine) can better track how advanced prostate cancer responds to treatment compared to standard CT and bone scans. Nine men with metastatic castration-resistant prostate cancer received the scan before and 12 weeks after starting life-prolonging therapies. The goal was to see if the PET scan detects changes in tumors more sensitively, potentially guiding better treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-fluciclovine (Axumin) PET scan
What this could lead to: If successful, this could lead to more accurate monitoring of prostate cancer treatment response, helping doctors tailor therapies earlier.
What could go wrong: This is a very small pilot study with only 9 participants, so results may not apply broadly. The scan is for monitoring, not treatment, and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Tulane Cancer Center Clinic

New Orleans, Louisiana, 70112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.